Anti-Domain I β2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study.

Date publication

juin 2020

Journal

The journal of applied laboratory medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis

Tous les auteurs :
Zuily S, de Laat B, Guillemin F, Kelchtermans H, Magy-Bertrand N, Desmurs-Clavel H, Lambert M, Poindron V, de Maistre E, Dufrost V, Risse J, Shums Z, Norman GL, de Groot PG, Lacolley P, Lecompte T, Regnault V, Wahl D,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32572467

Résumé

Antibodies binding to domain I of β2-glycoprotein I (aDI) and activated protein C (APC) resistance are associated with an increased risk of thrombosis in cross-sectional studies. The objective of this study was to assess their predictive value for future thromboembolic events in patients with antiphospholipid antibodies (aPL) or antiphospholipid syndrome.

Mots clés

Antiphospholipid antibodies, Antiphospholipid syndrome, lupus anticoagulant, systemic lupus erythematosus, β2-Glycoprotein I

Référence

J Appl Lab Med. 2020 Jun 23;: